Oncology
2 drugs are in development for Hodgkin Lymphoma.
- Companies
- 2
- Clinical trials
- 40
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hodgkin Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(2)
| Drug | Company |
|---|---|
| CTX-8371 | Compass Therapeutics, Inc. (CMPX) |
| mt-601 | Marker Therapeutics, Inc. (MRKR) |
About this indication
Hodgkin Lymphoma context
Oncology·MeSH: Hodgkin Disease (D006689)
Also known as: Disease, Hodgkin, Disease, Hodgkin's, Hodgkin Granuloma, Hodgkin's Granuloma, Hodgkins Lymphoma, Lymphogranulomas, Malignant, Malignant Granuloma, Malignant Granulomas, Malignant Lymphogranuloma
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Hodgkin Lymphoma?
BioSniper tracks 2 drugs in development for Hodgkin Lymphoma across 2 companies.
How many clinical trials target Hodgkin Lymphoma?
There are 40 clinical trials targeting Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Hodgkin Lymphoma?
The estimated prevalence of Hodgkin Lymphoma is approximately 56.0 per 100,000 population.